BCL2L12

Across TCGA pan-cancer cohorts, BCL2L12 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated BCL2L12 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher BCL2L12 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated BCL2L12 expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

LSCC, HNSC, and GBM are the cancer types where BCL2L12 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Quartile	All	1.000	0.562	.005	13	view →
HNSC	DFS	Quartile	All	1.000	0.578	.029	6	view →
GBM	DFS	Median	All	0.590	0.859	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

BCL2L12–LSCC (DFS)

Open the LSCC breakdown →